SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* LAPORTE KATHLEEN (Last) (First) (Middle) C/O VNUS MEDICAL TECHNOLOGIES, INC. 5799 FONTANOSO WAY (Street) SAN JOSE CA 95138 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol VNUS MEDICAL TECHNOLOGIES INC [ VNUS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/18/2008
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2008		M		750	A	$0.00	3,000	D
Common Stock								2,597,597	I	See Footnotes(1)(2)(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(5)	05/18/2008		M			750	(6)	(6)	Common Stock	750	$0.00	0	D

Explanation of Responses:

1. This information is derived from a Schedule 13G/A filed by Credit Suisse, a Swiss bank (the "Bank"), on behalf of its Investment Banking division, the Alternative Investments business and the U.S. private client services business with the Securities and Exchange Commission ("SEC") on February 14, 2008 (the "Schedule 13G/A"). The Bank, on behalf of its subsidiaries, to the extent that such subsidiaries constitute the Investment Banking Division (the "13G Persons"), reports beneficial ownership of the shares indicated with shared voting and investment power of these shares. The ultimate parent company of the Bank is Credit Suisse Group, a Swiss corporation ("CSG"), which, under the federal securities laws, may be deemed to control the Bank and the 13G Persons.

2. CSG, its executive officers and directors, and its direct and indirect subsidiaries, may beneficially own shares to which the Schedule 13G/A relates and shares not reported in the Schedule 13G/A. However, CSG disclaims beneficial ownership of the shares beneficially owned by its direct and indirect subsidiaries, including the 13G Persons.

3. Includes shares held directly by Sprout Capital IX, L.P., Sprout Capital VII, L.P., Sprout Capital VIII, L.P., DLJ First ESC, L.P., DLJ Capital Corporation ("DLJCC"), Sprout IX Plan Investors, L.P., DLJ ESC II, L.P., Sprout Venture Capital, L.P., Sprout CEO Fund, L.P., Sprout Entrepreneurs Fund, L.P. and Credit Suisse Securities (USA) LLC.

4. Kathleen D. LaPorte is a Managing Director of New Leaf Venture Partners, L.L.C. ("NLV"). NLV has entered into an agreement with DLJCC, which is an indirect subsidiary of the Bank. Pursuant to the agreement, NLV provides sub-management services for the Sprout investment portfolio. As a result of this relationship, Ms. LaPorte may be deemed to beneficially own the shares to which the Schedule 13G/A relates. Ms. LaPorte disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein.

5. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.

6. 25% of the restricted stock units vest every three (3) months measured from May 18, 2007, such that 100% of the restricted stock units were fully vested on May 18, 2008.

	Cindee Van Vleck, Attorney-in-Fact for Kathleen D. LaPorte	05/20/2008
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.